Biotech Showcase™ 2017: Seventure expects uptick in microbiome-focused VC investments

January 24, 2017
Having closed a EUR 160 million venture fund focusing exclusively on microbiome-related fields—including pharmaceuticals, nutrition, biomarkers and diagnostics—Seventure Partners president and CEO Isabelle de Cremoux tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, how she expects to add another 10 companies this year to the nine she already has in her portfolio.
Previous Video
Biotech Showcase™ 2017: Market-ready Advicenne seeks partners and EUR 40 million VC funds
Biotech Showcase™ 2017: Market-ready Advicenne seeks partners and EUR 40 million VC funds

With a focus on pediatric neurology and nephrology, Dr. Luc-André Granier, founder, CEO and medical directo...

Next Video
Biotech Showcase™ 2017: Digital medicine will drive meaningful personalized clinical outcomes
Biotech Showcase™ 2017: Digital medicine will drive meaningful personalized clinical outcomes

Medidata president and co-founder Glen de Vries shares with Mike Ward, Informa Pharma Intelligence’s insigh...